Articles

Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

The Ohio State University, Columbus, OH
MD Anderson Cancer Center, Houston, TX
Weill Cornell Medicine, New York, NY
Weill Cornell Medicine, New York, NY
Willamette Valley Cancer Institute, Eugene, OR
Georgetown University Hospital, Washington, DC
The Ohio State University, Columbus, OH
Acerta Pharma, South San Francisco, CA
Acerta Pharma, South San Francisco, CA
Acerta Pharma, South San Francisco, CA
Acerta Pharma, South San Francisco, CA
Acerta Pharma, South San Francisco, CA
Acerta Pharma, South San Francisco, CA
UC San Diego Moores Cancer Center, San Diego, CA
Haematologica Early view Mar 18, 2021 https://doi.org/10.3324/haematol.2020.272500